D
Daniela E. Oprea-Lager
Researcher at VU University Amsterdam
Publications - 118
Citations - 3546
Daniela E. Oprea-Lager is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Medicine & Prostate cancer. The author has an hindex of 18, co-authored 76 publications receiving 1211 citations. Previous affiliations of Daniela E. Oprea-Lager include European Organisation for Research and Treatment of Cancer & Leiden University Medical Center.
Papers
More filters
Journal ArticleDOI
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet,Roderick C.N. van den Bergh,Erik Briers,Thomas Van den Broeck,Marcus G. Cumberbatch,Maria De Santis,Maria De Santis,Stefano Fanti,Nicola Fossati,Giorgio Gandaglia,Silke Gillessen,Silke Gillessen,N. Grivas,Jeremy Grummet,Ann Henry,Theodorus H. van der Kwast,Thomas B. Lam,Thomas B. Lam,Michael Lardas,Matthew Liew,Malcolm David Mason,Lisa Moris,Daniela E. Oprea-Lager,Henk G. van der Poel,Olivier Rouvière,Ivo G. Schoots,Ivo G. Schoots,Derya Tilki,Thomas Wiegel,Peter-Paul M. Willemse,Philip Cornford +30 more
TL;DR: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa guidelines summarise the most recent findings and advice for their use in clinical practice and include a strong recommendation to consider moderate hypofractionation in intermediate-risk patients.
Journal ArticleDOI
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
Philip Cornford,Roderick C.N. van den Bergh,Erik Briers,Thomas Van den Broeck,Marcus G. Cumberbatch,Maria De Santis,Maria De Santis,Stefano Fanti,Nicola Fossati,Giorgio Gandaglia,Silke Gillessen,Nikolaos Grivas,Jeremy Grummet,Ann Henry,Theodorus H. van der Kwast,Thomas B. Lam,Thomas B. Lam,Michael Lardas,Matthew Liew,Malcolm David Mason,Lisa Moris,Daniela E. Oprea-Lager,Henk G. van der Poel,Olivier Rouvière,Ivo G. Schoots,Ivo G. Schoots,Derya Tilki,Thomas Wiegel,Peter-Paul M. Willemse,Nicolas Mottet +29 more
TL;DR: The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for use in clinical practice and guide the clinician in the discussion with the patient on the treatment decisions to be taken.
Journal ArticleDOI
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
Francesco Ceci,Daniela E. Oprea-Lager,Louise Emmett,Judit A. Adam,Jamshed Bomanji,Johannes Czernin,Matthias Eiber,Uwe Haberkorn,Michael S Hofman,Thomas A. Hope,Rajesh Kumar,Steven P. Rowe,Sarah Schwarzenboeck,Stefano Fanti,Ken Herrmann +14 more
TL;DR: The E-PSMA standardized reporting guidelines, a document supported by the European Association of Nuclear Medicine (EANM), provide consensus statements among a panel of experts in PSMA-PET imaging, to develop a structured report for prostate cancer and to harmonize diagnostic interpretation criteria as mentioned in this paper.
Journal ArticleDOI
Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.
Nandita M. deSouza,Yan Liu,Arturo Chiti,Daniela E. Oprea-Lager,Géraldine Gebhart,Bernard E. Van Beers,Ken Herrmann,Frédéric Lecouvet +7 more
TL;DR: Optimal standardised imaging approaches will enable OMD trials to document patterns of disease progression and outcomes of treatment, and quality assured and quality controlled imaging data included in databases will establish a large and high-quality imaging warehouse for future research.
Journal ArticleDOI
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Stefano Fanti,Karolien Goffin,Boris Hadaschik,Ken Herrmann,Tobias Maurer,Steven MacLennan,Daniela E. Oprea-Lager,Wim J.G. Oyen,Wim J.G. Oyen,Olivier Rouvière,Nicolas Mottet,Anders Bjartell +11 more
TL;DR: A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it.